The U.S. Food and Drug Administration has been working for years on rules for products containing cannabis-derived compounds like CBD. But nothing has yet materialized.
The research comes amid a broader agency effort to collect data on cannabinoids, which will help shape forthcoming rules on approved products.
The 2018 Farm Bill legalized hemp, and, by extension, hemp-derived CBD, but the Food and Drug Administration has not yet released rules to guide the growing industry.
The Food and Drug Administration has said for years that it is working on rules for cannabinoid-containing products. But it has also said that crucial research and data are lacking.
The federal law on cannabis has remained unchanged for more than half a century. Yet as states race toward legalization, federal agencies have begun to play catch up.
A policy coordinator with the FDA’s Cannabis Product Committee spoke about CBD during a Food and Drug Law Institute event focused on cannabis.
The Food and Drug Administration has been on a march to collect cannabinoid-related data. The “Cannabis-Derived Products Data Acceleration Plan” released this month is its most robust effort.
Epidiolex strikes again: the FDA-approved CBD-based pharmaceutical is complicating other uses of CBD.
CSU Pueblo hosted a pharmacist at Greenwich Biosciences to talk about the company’s path with Epidiolex, a CBD-based medicine extracted from cannabis plants.
The group, which includes Coca-Cola and Kellogg’s as members, says its membership is “CBD curious” but that the lack of federal regulation is keeping major brands at bay.
“I’m getting very hopeful that we're headed down the road to seeing some hemp-derived ingredients approved for use in animal food,” said the FDA’s Deputy Director in the Division of Animal Feeds.
The FDA, which has been crafting rules for CBD products since 2019, says it is seeking partnerships, from academia to government and the cannabis industry, to “develop the foundation for more robust CBD data collection.”
The Food and Drug Law Institute is hosting officials from several federal agencies this week to discuss cannabis policies.
One company is focused on the future of CBD in supplements. The other, on its future in pharmaceuticals.
During a recent webinar, the FDA detailed how its Drug Master Files process could speed up research, while keeping proprietary information secret.
Among the new names on the list of entities seeking to discuss the FDA’s forthcoming rules on CBD products: American Bankers Association and Columbia Care.